
doi: 10.1002/pu.31276
Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended‐release quetiapine in patients with treatment‐resistant depression (TRD). The additional analyses of the ESCAPE‐TRD trial used multiple thresholds for remission and relapse. Study results were published online Dec. 2, 2024, in The British Journal of Psychiatry.
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
